Data / Form D filings / Hexamer Therapeutics, Inc
Hexamer Therapeutics, Inc: Form D filings
Hexamer Therapeutics, Inc, a biotechnology company in Pullman, WA, filed 3 Form D notices with the SEC between 2019 and 2026. The latest, on September 15, 2026, reports $500,000 sold of a $2.5 million offering to 2 investors.
SpecStream is the live web data engine for teams and agents. It reads every Form D on SEC EDGAR the day it is filed, and this page is that reading. Ask for your own cut (a state, an industry, a size) and new filings arrive in your sheet, CRM, Slack or agent as they land.
Company details from the filing
- Address
- 2345 NE HOPKINS CT, Pullman, WA, 99163
- Phone
- (509) 715-9251
- Industry
- Biotechnology
- Entity type
- Corporation
- Incorporated in
- Delaware
- Revenue range
- Decline to Disclose
- Exemptions claimed
- Rule 506(b)
- SEC identifier (CIK)
- 1797915
Form D filings
| Filed | Type | Offering | Sold | Remaining | Investors | First sale | Filing |
|---|---|---|---|---|---|---|---|
| Sep 15, 2026 | New notice | $2,500,000 | $500,000 | $2,000,000 | 2 | Jul 7, 2026 | sec.gov |
| Jun 27, 2024 | New notice | $6,640,000 | $651,265 | $5,988,735 | 9 | Jan 1, 2024 | sec.gov |
| Dec 27, 2019 | New notice | $1,100,000 | $469,725 | $630,275 | 3 | Nov 15, 2019 | sec.gov |
Executive officers and directors named in the filing
| Name | Role | Note in the filing |
|---|---|---|
| Robert H Bogden | Executive Officer, Director | |
| Colin Collins | Director | |
| Keith Miller | Director | |
| R. Scott Blackley | Director | |
| Stephen Crawford | Director | |
| Brad Call | Director |
Other biotechnology companies in Washington that filed recently
- Key Proteo, Inc. $2.3 million · Oct 23, 2026
- Inmedix, Inc. $4 million · Oct 22, 2026
- Q-Immune, Inc. $25,000 · Sep 28, 2026
- MalarVx, Inc. $125,000 · Aug 25, 2026
- Strella Biotechnology, Inc. $1.8 million · Aug 14, 2026
- Automera US Inc. $1 million · Aug 7, 2026
Every Form D from the week of Sep 14, 2026 · All recent filings in Washington · All recent Biotechnology filings
Read from SEC EDGAR. Amount sold is what Hexamer Therapeutics, Inc reported on the day it filed; on an offering that is still open, a later amendment can raise it. Free to reuse with credit to SpecStream under CC BY 4.0.